| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
LONDON—After last summer having resolved roughly two-third of 26,000 lawsuits against it regarding claims that its antipsychotic drug Seroquel causes diabetes, AstraZeneca has reportedly agreed to pay $150 million to settle more lawsuits. This puts the total payout for settlements at nearly $350 million, reportedly, after the August payout of roughly $198 million.

The drug is the company's second-biggest-selling medication (cholesterol-reducing drug Crestor being the top seller), with 2010 sales of $5.3 billion.

According to sources close to the matter who are speaking anonymously to the media, this will resolve about 6,000 cases that allege AstraZeneca knew Seroquel could cause diabetes and failed to adequately warn patients.

This settlement should now leave the company with just under 4,000 remaining U.S. product-liability claims for Seroquel, according to a regulatory filing, "that have not been settled in principle."

Also hitting AstraZeneca's bottom line is the $738 million it had paid to defend Seroquel as of December 2010. Furthermore, the company agreed last year to pay $520 million to resolve U.S. allegations that it illegally marketed Seroquel for unapproved uses. 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue